supplement industry

Al Jazeera reports that the booming longevity industry — anti-ageing treatments, supplements and clinics promising longer, healthier lives — is outpacing the scientific evidence behind many of its claims. The piece suggests consumers are spending on interventions whose long-term benefits and risks remain largely unproven, raising concerns about hype, regulation and safety as the market grows.

Kobayashi Pharmaceutical, the Japanese maker at the center of a supplement contamination scandal linked to suspected deaths, is reportedly considering a buyout offer worth more than ¥500 billion. The move would mark a major development for a company whose reputation and finances were badly damaged by the scandal, and market watchers are closely following what a takeover could mean for its future.

Nutrition industry publication Nutritional Outlook is highlighting what it calls the safety versus efficacy gap, a tension between supplement ingredients shown to be safe and those proven effective. The piece raises questions about how products are formulated and marketed when safety data outpaces efficacy evidence, a recurring debate among regulators, manufacturers and consumers in the global nutrition sector.

A new market forecast projects steady growth in the global dietary supplements industry through 2035, with personalized nutrition and gut health products cited as the main drivers. Analysts point to rising consumer interest in tailored vitamins, probiotics and microbiome-focused formulations as manufacturers expand offerings. Industry observers say the wellness trend and growing health awareness are reshaping demand across major markets.